BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

INTRODUCTION: BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks. AIM: To report long‐term efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900134/
https://www.ncbi.nlm.nih.gov/pubmed/31621991
http://dx.doi.org/10.1111/hae.13853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900134/
https://www.ncbi.nlm.nih.gov/pubmed/31621991
http://dx.doi.org/10.1111/hae.13853

Ejemplares similares